PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Whitaker Cardiovascular Institute and Department of Medicine, Boston University School of Medicine, Boston, MA, USA. vherrera@bu.edu.\', \'Section of Pulmonary and Critical Care, Department of Medicine, Boston University School of Medicine, and Boston Medical Center, Boston, MA, USA.\', \'Whitaker Cardiovascular Institute and Department of Medicine, Boston University School of Medicine, Boston, MA, USA.\', \'Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women\'s Hospital, Harvard Medical School, Boston, MA, USA.\', \'Center for Digital Health, Berlin Institute of Health and Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.\', \'Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.\', \'General Clinical Research Center, Boston University School of Medicine, Boston, MA, USA.\', \'Department of Pathology and Laboratory Medicine, Flow Cytometry Core Facility, Boston University School of Medicine, Boston, MA, USA.\', \'Division of Neurocritical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.\', \'Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.\', \'Molecular Epidemiology Unit, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin and Berlin Institute of Health (BIH), Berlin, Germany.\', \'Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.\', \'Whitaker Cardiovascular Institute and Department of Medicine, Boston University School of Medicine, Boston, MA, USA. nruizo@bu.edu.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-022-09343-1
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 35379853
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • A targetable \'rogue\' neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all